$COR

Tyler Lauren M purchased $149K of COR

Tyler Lauren M purchased 550 shares of Cencora, Inc. (COR) at $270.23 ($0.15M total) on 2026-06-22.

Original reporting
SEC EDGAR · Tyler Lauren M
Published Jun 24, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$COR
Bullish
low confidence
Mentioned
$COR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase details (550 shares at $270.23; ~$148.6K total). This can marginally support sentiment but does not change earnings, guidance, or risk materially.

02

Market read

Useful for tracking insider activity, but the transaction size and lack of fundamental updates make it low-conviction for trading decisions.

03

What to watch

No 10b5-1 plan is noted, but the article provides no context on prior holdings, motivation, or whether other insiders made similar moves.

Relevance 5/10Novelty 5/10Timing: SEC Form 4 filed 2026-06-24 (transaction dated 2026-06-22).

Background

The article is an SEC Form 4 insider transaction disclosure for Cencora, Inc. (COR).

Company-level read

Ticker impact

$CORBullishLow confidence
Context

Cencora (COR) disclosed via SEC Form 4 that director Tyler Lauren M bought 550 shares at $270.23 on 2026-06-22 for ~$148.6K.

Expected impact

Likely limited near-term price impact; any effect is small and sentiment-driven.

Evidence & confidence

The filing is a routine Form 4 insider transaction with no 10b5-1 plan and no accompanying company-specific operational or financial update.

Market effects

Minimal; insider buying at a single healthcare distributor does not materially change sector fundamentals.

None indicated.

None indicated.

Counterpoint

Insider purchases can be discretionary, tax/portfolio-driven, or small relative to typical trading volumes, so they may not reflect a new view on fundamentals.

Key entities

  • Cencora, Inc.

    Issuer of the Form 4 insider transaction; director Tyler Lauren M purchased shares.

  • Tyler Lauren M

    Director who reported an open-market purchase of 550 shares on 2026-06-22.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

HighAI 9/10

Cencora Agrees to Take Controlling Stake in American Oncology Network in $2.4 Billion Deal Spanning 21 States

Cencora agreed to acquire American Oncology Network (AON) for $2.4 billion, expanding its oncology services. The deal, pending approval, includes $2.3 billion at closing plus up to $100 million in contingent value rights. Cencora already owns 4% of AON and aims to increase its stake to 75%. The acquisition is part of a broader trend of drug wholesalers buying cancer practice management companies.

$CORHighAI 9/10

Cencora to buy American Oncology Network in $2.4bn deal

Cencora (COR) agreed to acquire American Oncology Network (AON) for $2.4bn, including $2.3bn at closing and up to $100m in contingent value rights. COR shares fell 4.84% post-announcement, despite recent gains. The deal expands COR's oncology services into 12 new states. COR raised its fiscal 2026 EPS guidance to at least $17.90. The transaction requires regulatory approval and AON stockholder approval.

$CORHighAI 9/10

Cencora, Inc. (COR): Results of Operations and Financial Condition

Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CENCORA TO ACQUIRE AMERICAN ONCOLOGY NETWORK TO STRENGTHEN SUPPORT OF COMMUNITY ONCOLOGY Builds on Cencora’s MSO platform by adding complementary capabilities and expanding presence across twelve additional states CONSHOHOCKEN, PA & FORT MYERS, Fla., October 21, 2026

$CORHighAI 9/10

Cencora to acquire American Oncology Network for $2.4 billion

Cencora Inc. (NYSE:COR) will acquire American Oncology Network Inc. (OTCQX:AONC) for $2.4 billion, including $2.3 billion at closing and up to $100 million in contingent value rights. The deal will expand Cencora's oncology services platform. Cencora expects the acquisition to be accretive to earnings per share by the second year post-closing and updated its 2026 EPS guidance to at least $17.90. The transaction is subject to regulatory approvals and AON stockholder approvals.

$CORHighAI 9/10

Cencora, Inc. (COR) to Acquire American Oncology Network for $2.4B EV

Cencora (COR) agreed to acquire American Oncology Network for $2.4B EV, with $2.3B paid at closing and up to $100M in contingent value rights. Cencora expects to pay about $1.7B for 75% ownership if 25% equity is rolled. The deal is expected to be EPS accretive in year two, subject to approvals. According to Cencora, the acquisition aligns with its strategy to expand in oncology services.

HighAI 8/10

Cancer-practice support would expand to 12 more states under Cencora's planned acquisition

Cencora plans to acquire American Oncology Network (AON), expanding its oncology services to 12 more states. The deal aims to enhance care access and support independent practices. Cencora expects the acquisition to be accretive to its adjusted diluted EPS in the second year post-closing. The transaction is subject to regulatory approvals and AON stockholder approvals.